Since leukemia cells harboring FLT3-ITD mutations are more sensitive to 2-DG treatment than wild-type cells, 2-DG may serve as a promising therapeutic target for AML patients with mutated FLT3. The gene discussed is FLT3; the disease is acute myeloid leukemia.